Gastrointestinal Involvement in Extra-Digestive Disease: Which Is the Role of Fecal Calprotectin?
Abstract
:1. Introduction
2. Fecal Calprotectin and Rheumatologic Diseases
2.1. Ankylosing Spondylitis
2.2. Behcet Diseases
3. Fecal Calprotectin and Dermatological Diseases
3.1. Psoriasis
3.2. Atopic Dermatitis
4. Fecal Calprotectin and Neurological Diseases
4.1. Parkinson’s Disease
4.2. Alzheimer’s Disease
5. Fecal calprotectin and COVID-19
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Poullis, A.; Foster, R.; Mendall, M.A.; Fagerhol, M.K. Emerging role of calprotectin in gastroenterology. J. Gastroenterol. Hepatol. 2003, 18, 756–762. [Google Scholar] [CrossRef] [PubMed]
- Jukic, A.; Bakiri, L.; Wagner, E.F.; Tilg, H.; Adolph, T.E. Calprotectin: From biomarker to biological function. Gut 2021, 70, 1978–1988. [Google Scholar] [CrossRef] [PubMed]
- Cypers, H.; Varkas, G.; Beeckman, S.; Delanghe, J.; Van den Bosch, F.; Elewaut, D. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann. Rheum. Dis. 2016, 75, 1357–1362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mulak, A.; Koszewicz, M.; Panek-Jeziorna, M.; Koziorowska-Gawron, E.; Budrewicz, S. Fecal Calprotectin as a Marker of the Gut Immune System Activation Is Elevated in Parkinson’s Disease. Front. Neurosci. 2019, 13, 992. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khaki-Khatibi, F.; Qujeq, D.; Kashifard, M.; Moein, S.; Maniati, M.; Vaghari-Tabari, M. Calprotectin in inflammatory bowel disease. Clin. Chim. Acta 2020, 510, 556–565. [Google Scholar] [CrossRef]
- Tibble, J.A.; Sigthorsson, G.; Foster, R.; Scott, D.; Fagerhol, M.K.; Bjarnason, I. High prevalence of NSAID enteropathy as shown by a simple fecal test. Clin. Trial Gut 1999, 45, 362–366. [Google Scholar]
- Blad, N.; Palmqvist, R.; Karling, P. Pre-diagnostic fecal calprotectin levels in patients with colorectal cancer: A retrospective study. BMC Cancer 2022, 22, 315. [Google Scholar] [CrossRef]
- De Pessemier, B.; Grine, L.; Debaere, M.; Maes, A.; Paetzold, B.; Callewaert, C. Gut-Skin Axis: Current Knowledge of the Interrelationship between Microbial Dysbiosis and Skin Conditions. Microorganisms 2021, 9, 353. [Google Scholar] [CrossRef]
- Arck, P.; Handjiski, B.; Hagen, E. Is there a ‘gut-brain-skin axis’? Exp. Dermatol. 2010, 19, 401–405. [Google Scholar] [CrossRef]
- Bowe, W.P.; Logan, A.C. Acne vulgaris, probiotics and the gut-brain-skin axis—Back to the future? Gut Pathog. 2011, 3, 1. [Google Scholar] [CrossRef] [Green Version]
- Gracey, E.; Vereecke, L.; McGovern, D.; Fröhling, M.; Schett, G.; Danese, S.; De Vos, M.; Van den Bosch, F.; Elewaut, D. Revisiting the gut–joint axis: Links between gut inflammation and spondyloarthritis. Nat. Rev. Rheumatol. 2020, 16, 415–433. [Google Scholar] [CrossRef]
- Liu, L.; Wang, H.; Chen, X.; Xie, P. Gut microbiota: A new insight into neurological diseases. Chin. Med. J. 2022, 10, 1097. [Google Scholar] [CrossRef] [PubMed]
- Vural, M.; Gilbert, B.; Üstün, I.; Caglar, S.; Finckh, A. Mini-Review: Human Microbiome and Rheumatic Diseases. Front. Cell. Infect. Microbiol. 2020, 10, 491160. [Google Scholar] [CrossRef] [PubMed]
- Klingberg, E.; Carlsten, H.; Hilme, E.; Hedberg, M.; Forsblad-d’Elia, H. Calprotectin in ankylosing spondylitis—Frequently elevated in feces, but normal in serum. Scand. J. Gastroenterol. 2012, 47, 435–444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bubová, K.; Forejtová, Š.; Zegzulková, K. Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: Baseline clinical characteristics and subset differences in a single-centre cohort. BMJ Open 2018, 9, e024713. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kang, K.Y.; Park, S.H.; Hong, Y.S. Relationship between fecal calprotectin and inflammation in peripheral joints and entheses in axial spondyloarthritis. Scand. J. Rheumatol. 2020, 49, 397–404. [Google Scholar] [CrossRef] [PubMed]
- Gazim, C.C.; Borba, A.A.; Castro, G.K.P.; Skare, T.L. Fecal calprotectin levels in acute anterior uveitis in patients with spondyloarthritis. Arq. Bras. Oftalmol. 2022, 10, 5935. [Google Scholar]
- Olofsson, T.; Lindqvist, E.; Mogard, E.; Wallman, J.K. Elevated fecal calprotectin is linked to worse disease status in axial spondyloarthritis: Results from the SPARTAKUS cohort. Rheumatology 2019, 58, 1176–1187. [Google Scholar] [CrossRef]
- Ercalik, C.; Baskaya, M.C.; Ozdem, S.; Butun, B. Investigation of asymptomatic intestinal inflammation in ankylosing spondylitis by fecal calprotectin. Arab J Gastroenterol. 2021, 22, 272–277. [Google Scholar] [CrossRef]
- Ma, Y.; Fan, D.; Xu, S. Calprotectin in spondyloarthritis: A systematic review and meta-analysis. Int. Immunopharmacol. 2020, 88, 106948. [Google Scholar] [CrossRef]
- Emad, Y.; Ragab, Y.; Hammam, N. The Clinical Utility of Fecal Calprotectin in Patients with Differentiated and Undifferentiated Spondyloarthritis: Relevance and Clinical Implications. Reumatol. Clin. 2020, 10, 1016. [Google Scholar]
- Özşeker, B.; Şahin, C.; Özşeker, H.S.; Efe, S.C.; Kav, T.; Bayraktar, Y. The Role of Fecal Calprotectin in Evaluating Intestinal Involvement of Behçet’s Disease. Dis. Markers 2016, 2016, 5423043. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Esatoglu, S.N.; Hatemi, I.; Ozguler, Y.; Yaziki, H. Fecal but not serum calprotectin levels look promising in predicting active disease in Behçet’s syndrome patients with gastrointestinal involvement. Clin. Exp. Rheumatol. 2018, 36, 90–96. [Google Scholar] [PubMed]
- Rendon, A.; Schäkel, K. Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci. 2019, 20, 1475. [Google Scholar] [CrossRef] [Green Version]
- Sikora, M.; Stec, A.; Chrabaszcz, M.; Rudnick, L. Clinical Implications of Intestinal Barrier Damage in Psoriasis. J. Inflamm. Res. 2021, 14, 237–243. [Google Scholar] [CrossRef]
- Madland, T.M.; Björkkjaer, T.; Brunborg, L.A.; Fröyland, L.; Berstad, A.; Brun, J.G. Subjective improvement in patients with psoriatic arthritis after short-term oral treatment with seal oil. A pilot study with double blind comparison to soy oil. J. Rheumatol. 2006, 33, 307–310. [Google Scholar]
- Haidmayer, A.; Bosch, P.; Lackner, A.; D’Orazio, M.; Fessler, J.; Stradner, M.H. Effects of Probiotic Strains on Disease Activity and Enteric Permeability in Psoriatic Arthritis-A Pilot Open-Label Study. Nutrients 2020, 12, 2337. [Google Scholar] [CrossRef]
- Seo, S.C.; Ahn, S.H.; Ri, S. Elevated fecal calprotectin levels are associated with severity of atopic dermatitis in children. Asian Pac. J. Allergy Immunol. 2018, 36, 82–87. [Google Scholar]
- Orivuori, L.; Mustonen, K.; De Goffau, M.C. High level of fecal calprotectin at age 2 months as a marker of intestinal inflammation predicts atopic dermatitis and asthma by age 6. Clin. Exp. Allergy 2015, 45, 928–939. [Google Scholar] [CrossRef]
- Schwiertz, A.; Spiegel, J.; Dillmann, U. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson’s disease. Park. Relat. Disord. 2018, 50, 104–107. [Google Scholar] [CrossRef]
- Devos, D.; Lebouvier, T.; Lardeux, B.; Nguyen, J.M.; Neunlist, M.; Derkinderen, P. Colonic inflammation in Parkinson’s disease. Neurobiol. Dis. 2013, 50, 42–48. [Google Scholar] [CrossRef] [PubMed]
- Becker, A.; Schmartz, G.P.; Groger, L.; Grammes, N.; Schwiertz, A.; Spiegel, J.; Wagenpfeil, G.; Faßbender, K.; Keller, A.; Unger, M.M. Effects of Resistant Starch on Symptoms, Fecal Markers and Gut Microbiota in Parkinson’s Disease—The RESISTA-PD Trial. Genom. Proteom. Bioinform. 2021. [Google Scholar] [CrossRef] [PubMed]
- Hor, J.W.; Lim, S.Y.; Khor, E.S.; Ju Teh, C.S.; Wie Chong, C.; Hilmi, I.N.; Tan, A.I. Fecal Calprotectin in Parkinson’s Disease and Multiple System Atrophy. J. Mov. Disord. 2022, 15, 106–114. [Google Scholar] [CrossRef] [PubMed]
- Sturgeon, C.; Fasano, A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers 2016, 4, e1251384. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dumitrescu, L.; Marta, D.; Dănău, A.; Popescu, B.O. Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson’s Disease. Front. Neurosci. 2021, 15, 689723. [Google Scholar] [CrossRef] [PubMed]
- Leblhuber, F.; Geisler, S.; Steiner, K.; Fuchs, D.; Schütz, B. Elevated fecal calprotectin in patients with Alzheimer’s dementia indicates leaky gut. J. Neural. Transm. 2015, 122, 1319–1322. [Google Scholar] [CrossRef] [PubMed]
- Horvath, I.; Jia, X.; Johansson, P. Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer’s Disease. ACS Chem. Neurosci. 2016, 7, 34–39. [Google Scholar] [CrossRef] [PubMed]
- Stolzenberg, E.; Berry, D.; Yang, D.; Barbut, D.; Zasloff, M.A. A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity. J. Innate Immun. 2017, 9, 456–463. [Google Scholar] [CrossRef]
- Köhler, C.A.; Maes, M.; Slyepchenko, A.; Berk, M.; Solmi, M.; Lanctôt, K.L.; Carvalho, A.F. The gut-brain axis, including the microbiome, leaky gut and bacterial translocation: Mechanisms and pathophysiological role in Alzheimer’s disease. Curr. Pharm. Des. 2016, 22, 6152–6166. [Google Scholar] [CrossRef]
- Franceschi, F.; Ojetti, V.; Candelli, M.; Covino, M.; Cardone, S.; Potenza, A.; Simeoni, B.; Gabrielli, M.; Sabia, L.; Gasbarrini, G.; et al. Microbes and Alzheimer’ disease: Lessons from H. pylori and GUT microbiota. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 426–430. [Google Scholar]
- Ojetti, V.; Saviano, A.; Covino, M.; Acampora, N.; Troiani, E.; Franceschi, F. COVID-19 and intestinal inflammation: Role of fecal calprotectin. Dig. Liver Dis. 2020, 52, 1231–1233. [Google Scholar] [CrossRef] [PubMed]
- Shokri-Afra, H.; Alikhani, A.; Moradipoodeh, B.; Noorbakhsh, F.; Fakheri, H.; Moradi-Sardareh, H. Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms. Sci. Rep. 2021, 11, 22001. [Google Scholar] [CrossRef] [PubMed]
- Udeh, R.; Advani, A.; De Guadiana, R.G.; Dolja-Gore, R. Calprotectin, an Emerging Biomarker of Interest in COVID-19: A Systematic Review and Meta-Analysis. J. Clin. Med. 2021, 10, 775. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Saviano, A.; Candelli, M.; Zanza, C.; Piccioni, A.; Migneco, A.; Ojetti, V. Gastrointestinal Involvement in Extra-Digestive Disease: Which Is the Role of Fecal Calprotectin? Medicina 2022, 58, 1384. https://doi.org/10.3390/medicina58101384
Saviano A, Candelli M, Zanza C, Piccioni A, Migneco A, Ojetti V. Gastrointestinal Involvement in Extra-Digestive Disease: Which Is the Role of Fecal Calprotectin? Medicina. 2022; 58(10):1384. https://doi.org/10.3390/medicina58101384
Chicago/Turabian StyleSaviano, Angela, Marcello Candelli, Christian Zanza, Andrea Piccioni, Alessio Migneco, and Veronica Ojetti. 2022. "Gastrointestinal Involvement in Extra-Digestive Disease: Which Is the Role of Fecal Calprotectin?" Medicina 58, no. 10: 1384. https://doi.org/10.3390/medicina58101384